GENinCode Plc (LSE:GENI) has announced a new partnership with Mexico-based Sohin Genetics to distribute its CARDIO inCode-Score® test in the country. The agreement will introduce the company’s polygenic risk scoring tool for coronary heart disease to the Mexican market, where cardiovascular conditions remain a leading cause of mortality.
The collaboration is designed to broaden GENinCode’s commercial footprint in Mexico while supporting earlier identification and prevention of heart disease through personalised risk assessment. By improving predictive screening, the company believes the test could help lower the incidence of serious cardiovascular events and reduce long-term healthcare costs.
Despite ongoing financial pressures, including continued losses and negative cash flow, GENinCode has recently made progress through strategic partnerships and regulatory milestones that support future growth and product uptake. While valuation remains challenged due to negative earnings, technical indicators point to modest positive momentum in the company’s shares.
More about GENinCode UK Ltd.
GENinCode Plc is an Oxford-based predictive genetics company focused on cardiovascular disease prevention and ovarian cancer risk assessment. The group specialises in genetic risk prediction technologies and commercialises diagnostic tools such as the CARDIO inCode-Score® test to evaluate inherited risk factors for heart disease.
Leave a Reply